Transgene Biotek Limited Stock

Equities

TRABI6

INE773D01018

Biotechnology & Medical Research

Delayed Bombay S.E. 04:28:34 2024-04-24 am EDT 5-day change 1st Jan Change
7.5 INR +2.74% Intraday chart for Transgene Biotek Limited -2.22% -24.01%
Sales 2022 867K 10.41K Sales 2023 551K 6.62K Capitalization 189M 2.27M
Net income 2022 -104M -1.25M Net income 2023 -60M -721K EV / Sales 2022 454 x
Net Debt 2022 120M 1.44M Net Debt 2023 131M 1.57M EV / Sales 2023 580 x
P/E ratio 2022
-2.63 x
P/E ratio 2023
-3.14 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.32%
More Fundamentals * Assessed data
Dynamic Chart
Transgene Biotek Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter Ended September 30, 2023 CI
Transgene Biotek Limited Approves Closure of Subsidiary Company Peroral Bio Private Limited CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter Ended December 31, 2022 CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Transgene Biotek Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Transgene Biotek Limited Reports Earnings Results for the Third Quarter Ended December 31, 2021 CI
Transgene Biotek Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Transgene Biotek Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Transgene Biotek Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
More news
1 day+2.74%
1 week-2.22%
Current month-7.86%
1 month-10.61%
3 months-36.17%
6 months+82.93%
Current year-24.01%
More quotes
1 week
6.94
Extreme 6.94
7.95
1 month
6.94
Extreme 6.94
8.78
Current year
6.94
Extreme 6.94
12.46
1 year
2.36
Extreme 2.36
12.46
3 years
2.28
Extreme 2.28
12.46
5 years
2.01
Extreme 2.01
12.46
10 years
1.55
Extreme 1.55
12.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 81 90-12-31
Director of Finance/CFO - 19-05-23
Compliance Officer - 19-05-23
Members of the board TitleAgeSince
Chief Executive Officer 81 90-12-31
Director/Board Member 41 15-04-16
Director/Board Member - 19-11-11
More insiders
Date Price Change Volume
24-04-24 7.5 +2.74% 56 214
24-04-23 7.3 -1.08% 43,710
24-04-22 7.38 +1.23% 24,591
24-04-19 7.29 -4.95% 111,153
24-04-18 7.67 -3.52% 77,525

Delayed Quote Bombay S.E., April 24, 2024 at 04:28 am EDT

More quotes
Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
More about the company
  1. Stock Market
  2. Equities
  3. TRABI6 Stock